OR WAIT null SECS
Frost & Sullivan has released its "Drug Launch and Phase 3 Trial Watch List for Top Therapy Areas for 2015".
Oncology, cardiovascular, autoimmune/anti-inflammatories, and infectious diseases will be the top areas of investments in 2015, according to Frost & Sullivan. Pharma companies will also be keen to invest in in-vitro diagnostics such as biomarkers; molecular, tissue, companion diagnostics; predisposition disease; and predictive testing, added the company's Life Sciences Global Program Director, Jennifer Lazar. Frost & Sullivan has released its "Drug Launch and Phase 3 Trial Watch List for Top Therapy Areas for 2015". It includes:
In addition to new molecular entity product launches, Frost & Sullivan reports that there are "abundant opportunities for generic and biosimilar drugs due to the patent expiry of several blockbuster drugs in 2014 and 2015". Some of those include: